Prevention Of Stroke In Nonvalvular Atrial Fibrillation
Key Points
Key Points
- The absolute risk of stroke varies 20-fold among AF patients according to age and associated vascular comorbidities. Current AHA2 guidelines use the CHADS stratification scheme.
- The major risk of antithrombotic medications used to lower the incidence of AF-related stroke is bleeding.
- For warfarin, this involves balancing a bleeding risk of 1% to 12% per year.
- The advent of several new antithrombotic agents offers alternatives to warfarin and may lower the thromboembolic risk threshold for initiating therapy in patients with AF.
Diagnosis
...iagnos...
...Stroke Risk in Patients With Nonv...
Figure 1. Patterns of Atrial Fibrilla...
Treatment
Treatm...
...arin (A)300167...
...atran (B)300167...
...aban (B)300167
...oxaban (B)3001...
...fficacy of combining dabigatran, rivaroxaban, or...
... Clopidogrel & Warfarin...
...usted-dose warfarin (target INR – 2....
...herapy with aspirin is recommended...
...isk patients with AF deemed unsuitab...
...ents with ischemic stroke or TIA wit...
...irin alone is recommended. (A)300167
...ombination of clopidogrel plus aspirin ca...
Dabigatran
...ran is useful as an alternative to warfa...
...abigatran 150 mg twice daily is an efficacious alt...
...f pharmacokinetic data, the use of dabigat...
...there are no data to support the use of da...
...pixaban...
...an 5 mg twice daily is an efficacious a...
...gh its safety and efficacy have not been establi...
...an 5 mg twice daily is a relatively sa...
...its safety and efficacy have not...
...should NOT be used if the Cr...
Rivaroxaban
...ith nonvalvular AF who are at moderate to...
...patients with renal impairment and nonvalvular AF...
...aban should NOT be used if the CrCI...
...2. Agents Recommended for Stroke Preventio...
...2. Prevention of Stroke in Nonvalvular Atr...